Celgene – Introduction
The use of Revlimid as a front-line treatment in multiple myeloma should contribute approximately USD1bn to sales figures. Celgene’s overall pipeline momentum is positive and higher-than-expected sales from recent launches (e.g. Pomalyst for blood cancer) should further improve the company’s position. The 2017 EPS growth guidance looks conservative.
Link to the biotechnology-report: